SOBETIROME FOR TREATMENT OF MYELINATION DISORDER

摘要

PROBLEM TO BE SOLVED: To provide a method for treating a disorder or a condition concerning demyelination, insufficient myelination, or an insufficient growth of a medullary sheath.SOLUTION: Used is a noncardiotoxic medicine (sobetirome) effective for CNS and capable of reducing demyelination and promoting medullary sheath formation without causing thyroid toxemia. The sobetirome and a pharmaceutically permitted salt provide a treatment executable for preventing or recovering from demyelination in a disorder such as multiple sclerosis (MS), and another disorder or a condition concerning demyelination, insufficient myelination, or an insufficient growth of a medullary sheath. A method for treating a target having a neurodegenerative disease or a condition concerning demyelination, insufficient myelination, or an insufficient growth of a medullary sheath or a risk of suffering from such a disease is provided. This method includes administering a treatment effective dose of sobetirome or a pharmaceutically permitted salt.SELECTED DRAWING: None